Novo Nordisk at ObesityWeek 2026
Nov 14–17, 2026 National Harbor, MD ~4.4k attendees Website
Novo Nordisk brings 16 presentations to ObesityWeek 2026 in National Harbor, and exhibits at Booth 309, 715, Suite 7, Suite 7a, Suite 7b. Its program centers on semaglutide, including real-world results with the oral form and what patients and clinicians prefer in obesity medicines, plus the amylin-based drugs cagrilintide and CagriSema. One concrete item is how cagrilintide protects bone mass during weight loss.
| Organization | ObesityWeek 2026 Attendance |
|---|---|
Novo Nordisk Bagsværd, Denmark | ◆Platinum Sponsor |
Global healthcare company with a century of diabetes medicines, also treating obesity and rare blood and endocrine disorders, with its US arm in New Jersey. | Booth Exhibiting at Booth 309, 715, Suite 7, Suite 7a, Suite 7b Sat, Nov 147pm–9:30pmSun, Nov 159:30am–4pmMon, Nov 169:30am–4pm Talk Sat Nov 14 11:45am–1:15pm The Missing Piece in the Obesity Puzzle: Exploring the Immunobiology of Obesity and the Role of Amylin Explores obesity-related inflammation, how current drugs affect it, and evidence for emerging amylin-based therapies, including combined GLP-1 and amylin drugs. Metabolism and integrative physiologyClinical obesity care and professional practiceObesity pharmacotherapy and drug development Poster Sat Nov 14 7:30pm–8:30pm Real-World Weight Outcomes with Semaglutide 1.0, 1.7, and 2.4 mg in the US and UK (STEP ADAPT Real) Chronic disease and obesity complications Talk Sun Nov 15 9:45am–10:15am Evidence Snapshot: Addressing Weight and CV Risk in Patients with Obesity Reviews cardiovascular outcomes and chronic weight-management trial data in adults with overweight or obesity, with dosing and administration considerations. Interventional and clinical studiesClinical obesity care and professional practiceObesity pharmacotherapy and drug developmentChronic disease and obesity complications Poster Sun Nov 15 2:30pm–3:30pm Cagrilintide’s Potential Benefits on Bone Health via Proteomics in Adults With Over-Weight or Obesity Obesity pharmacotherapy and drug developmentInterventional and clinical studies Poster Sun Nov 15 2:30pm–3:30pm AWS Cloud–First Data Discovery for Pragmatic Clinical Trial Linkage Interventional and clinical studiesObesity pharmacotherapy and drug development Poster Sun Nov 15 2:30pm–3:30pm Preferences for Obesity Medications Among Health Care Professionals Interventional and clinical studies Poster Sun Nov 15 2:30pm–3:30pm Obesity Medication Preferences Among Younger and Older Adults: An Age-Stratified Analysis Interventional and clinical studies Poster Sun Nov 15 2:30pm–3:30pm Real-World Weight Outcomes and Patient Experience with Oral Semaglutide in a Digital Support Cohort Interventional and clinical studies Poster Sun Nov 15 2:30pm–3:30pm 3-Month Food Noise and Patient-Reported Outcomes with Oral Semaglutide for Overweight or Obesity Obesity pharmacotherapy and drug developmentInterventional and clinical studies Poster Sun Nov 15 2:30pm–3:30pm Characteristics of Early Initiators of Oral Semaglutide for Overweight or Obesity via Telehealth Obesity pharmacotherapy and drug developmentPolicy and public health Talk Sun Nov 15 6:30pm–9:00pm Obesity in Focus: Today's Evidence. Tomorrow's Possibilities. Speakers cover what has changed in obesity guidelines, evidence behind approved obesity drugs, and the biology of amylin and new amylin analog data. Interventional and clinical studiesClinical obesity care and professional practiceNutrition, diet and foodObesity pharmacotherapy and drug development Talk Mon Nov 16 11:30am–1:15pm The Evolution of Obesity Management: Incorporating a Maturing Science into Clinical Practice Case-based discussion of treating obesity as a lifelong chronic disease, with personalized drug choice, combination therapy and continued treatment. Clinical obesity care and professional practiceObesity pharmacotherapy and drug development Poster Mon Nov 16 2:30pm–3:30pm The Predicted Impact of CagriSema on Cardiovascular Disease in US Adults With Overweight or Obesity Population health and epidemiologyNutrition, diet and food Poster Mon Nov 16 2:30pm–3:30pm Changes in Purchasing Behavior Following Initiation of GLP-1RAs: Data from a UK Consumer Panel Population health and epidemiologyNutrition, diet and food Poster Mon Nov 16 2:30pm–3:30pm Talk Mon Nov 16 5:00pm–5:15pm |
Find decision makers at Novo Nordisk
Tell us what you sell and we’ll find the people at Novo Nordisk most likely to buy it.
- Who to contact
- Their contact info
- What to say
- Free, no sign-up
Not affiliated with or endorsed by The Obesity Society (TOS), ObesityWeek® or the American Society for Metabolic and Bariatric Surgery (ASMBS). Submit a correction